Rare and childhood cancer multi-omics for precision medicine

Recruiting

• Conditions: High-risk neuroblastoma, refractory or relapsedOsteosarcomaNon-rhabdosarcoma solid tumorsBrain tumors: embryonal tumors & diffused/high grade gliomasAtypical teratoid/rhabdoid tumor; Neuroblastoma; Osteosarcoma; Non-rhabdosarcoma solid tumors; Embryonal brain tumors; Diffused/high grade gliomas; Atypical teratoid/rhabdoid tumor

• Registration Number: TCTR20211015001
• Lead Sponsor: Health System Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-15
• Last Update Posted: 19 August 2024
• Study Completion: 2024-12-30

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Age less than 18 years with High-risk neuroblastoma, refractory or relapsed or Osteosarcoma or Non-rhabdosarcoma solid tumors or Brain tumors: embryonal tumors & diffused/high grade gliomas or Atypical teratoid/rhabdoid tumor

Exclusion Criteria

1. No biological parents available
2. Refusal to participate in the study

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cancer predisposing gene 1 month Not statistical method

Secondary Outcome Measures

Name	Time	Method
ovel targeted therapy 6 months Not statistical method